NEUROCRINE BIOSCIENCES INC Recognition of Deferred Revenue
NEUROCRINE BIOSCIENCES INC (NBIX) reported Recognition of Deferred Revenue of $27.79 million for the 9-month period ending 2011-09-30, per its 10-Q filed 2011-10-31.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2011-10-31
- NEUROCRINE BIOSCIENCES INC recognition of deferred revenue for the quarter ending 2011-09-30 was $9.24M.
- NEUROCRINE BIOSCIENCES INC recognition of deferred revenue for the quarter ending 2010-09-30 was -$772.00K.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 6 month | Recognition of Deferred Revenue 9 month |
|---|---|---|---|
| 2011-09-30 | $9.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $27.79M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $18.55M 10-Q · filed 2011-07-29 | ||
| 2010-09-30 | -$772.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | -$71.66M 10-Q · filed 2011-10-31 | |
| 2010-06-30 | -$70.89M 10-Q · filed 2011-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |